Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm

If you purchased or acquired WGS common stock between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648. Click here to participate in the action. NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- What’s Happening? Bragar Eagel & Squire, P.C ., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) in the United States District Court for the District of Connecticut on behalf of all persons and entities who purchased or otherwise acquired WGS common stock between April 16, 2025 and May 4, 2026 , both dates inclusive (the “Class Period”). Investors have until August 3, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details? The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company may have misled investors about the importance of Fabric Genomics; (2) as a result, the Company’s margins would suffer; (3) the company’s average reimbursement rates were not as “durable” as previously disclosed; (4) as a result of the foregoing, the Company’s gross margins would decline; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis. On May 4, 2026, GeneDx rel...